News
We send the latest information from SMC Laboratories.
Gilead Sciences, Inc. presented results of the phase 2b ATLAS trial at EASL ~The Digital International Liver Congress™ 2020 ~
Gilead Sciences, Inc. (USA) presented on August, 2020, the results of the phase 2b trial for NASH cirrhosis at EASL ~The Digital International Liver Congress™ 2020 ~. For detailed information, see the below URL. https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Improvement of NASH cirrhosis has been reported by combination of cirofexor (FXR agonist) and firsocostat (ACC inhibitor). Combination…
Our clients’ presentations at EASL ~The Digital International Liver Congress™ 2020 ~
Our clients presented data on treatment of NASH using STAMTM model at the EASL ~The Digital International Liver CongressTM 2020~ (August 27-29). For detailed information, see the below URL. https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Poster #FRI105 Therapeutic efficacy of the chitotriosidase inhibitors in STAM model of non-alcoholic steatohepatitis Institution: OncoArendi Therapeutics SA (Paland) Poster #FRI119 Novel…
Galectin Therapeutics announces commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (GR-MD-02) in NASH cirrhosis
Galectin Therapeutics (USA) announced on June 30, 2020, the commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (R-MD-02) in NASH cirrhosis. For detailed information, see the below URL. https://investor.galectintherapeutics.com/news-releases/news-release-details/update-galectin-therapeutics-announces-commencement-patient Belapectin is a galectin-3 inhibitor. The compound used the STAMTM mouse model for non-clinical studies, and data showing the improvement…
Terns Pharmaceuticals Inc. announced that initiation of patient dosing in the LIFT study, a phase 2A clinical trial of TERN-101 in development for NASH
Terns Pharmaceuticals Inc. (USA and Shanghai) announced on 23 July, 2020, the initiation of patient dosing in the Phase2A study (LIFT study) of TERN-101 in development for NASH. TERN-101 is FXR agonist. This compound is a non-bile acid FXR agonist unlike Intercept's FXR agonist (OCA), which was recently dropped, and is expected to have…
NIDDK's publication in Purinergic Signaling
SMC announces that NIDDK (MD) has published the results of a study using the STAMTM mouse model in Purinergic Signaling. Title: “Design and in vivo activity of A3 adenosine receptor agonist prodrugs” https://link.springer.com/article/10.1007/s11302-020-09715-0 In this paper, they report the results of a pharmacology study of a A3 adenosine receptor agonist prodrug (MRS7476) using…
Genfit announced that it will discontinue the Phase 3 NASH study and concentrate on the developmento of PBC therapeutics.
Genfit (France) announced on July 22, 2020, that it will discontinue Elafibranor's Phase 3 NASH clinical trial and concentrate on developing PBC therapeutics. RESOLVE-IT Phase 3 clinical trial did not show any improvement in the primary endpoint, resulting in a change in corporate strategy. Following the recent news of OCA, the drop of Elafibranor,…
Merck's publication in Cell Reports Medicine
SMC announces that Merck & Co., Inc. (NJ) has published the results of a study using STAMTM mouse model in Cell Reports Medicine. Title: “Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis” In this paper, they report the results of pharmacology study of MK-8722 (AMPK activator) and MK-4074 (ACC inhibitor) using…
DURECT has published a news release regarding positive topline data from phase 1b study of DUR-928 in NASH
DURECT CORPORATION (USA) announced on May 26, 2020, that positive topline data was obtained in serum liver enzymes (ALT, AST, GGT) and liver stiffness as measured by Fibroscan in the Phase 1b for NASH patients. DUR-928 is a endogenous epigenetic regulator. The compound used the STAMTM mouse model for non-clinical studies, and data showing…
FDA rejects Intercept Pharma's drug for NASH for now
Intercept Pharmaceuticals, Inc. (USA) announced that it has received a notification from the FDA that it will not approve the application for FXAR agonist (OCA) for liver fibrosis by NASH on June 29, 2020. OCA has reported to have side efects such as itching and an increase in total cholesterol level. The announce is…
Hepion pharma has publshed a pres releaes regarding the CRV431 efficacy evaluation study for kidney fibrosis we have provied.
Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model. CRV431 is a cyclophillin inhibitor. In addition to the UUO mouse model, this compound exerts its anti-fibrosis effects in other fibrosis models such as the STAMTM mouse model, and is expected for future clinical development. …